Your browser doesn't support javascript.
loading
Study on the mechanism of quercetin in Sini Decoction Plus Ginseng Soup to inhibit liver cancer and HBV virus replication through CDK1.
Hao, Liyuan; Li, Shenghao; Chen, Guo; Nie, Aiyu; Zeng, Liang; Xiao, Zhonghui; Hu, Xiaoyu.
Afiliación
  • Hao L; Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
  • Li S; Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
  • Chen G; Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
  • Nie A; Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
  • Zeng L; Shijiazhuang Fifth Hospital, Shijiazhuang, Hebei, P.R. China.
  • Xiao Z; Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
  • Hu X; Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
Chem Biol Drug Des ; 103(6): e14567, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38858165
ABSTRACT

BACKGROUND:

To explore the anti-tumor and anti-virus key active ingredients of Sini Decoction Plus Ginseng Soup (SNRS) and their mechanisms.

METHODS:

The main ingredients of SNRS were analyzed by network pharmacology, and quercetin was identified as the key active ingredient. Then, we obtained the targets of quercetin by using Drugbank, PharmMapper, and SwissTargetPrediction databases. Then, the targets of HBV-related hepatocellular carcinoma (HBV-related HCC) were obtained by using Genecards database. In addition, using the gene expression profiles of HBV-related HCC patients in GEO database and the genes with the greatest survival difference in GEPIA 2 database identified the potential targets of quercetin. In addition, the mechanism of potential genes was studied through GO, KEGG analysis, and PPI network. Using AUC and survival analysis to evaluate the diagnostic and prognostic value of cyclin-dependent kinase 1 (CDK1) and CCNB1. Finally, the effects of quercetin on proliferation of Hep3B and HepG2215 cells and the level of CDK1 and CCNB1 were verified in vitro. ELISA was used to measure the expression levels of hepatitis B surface antigen (HBsAg) and hepatitis B e antigen (HBeAg) after the intervention by quercetin for 24 h and 48 h in HepG2215 cell.

RESULTS:

The first 10 key ingredients of SNRS were identified, and quercetin was the most key ingredient. The 101 potential quercetin targets were identified for the treatment of HBV-related HCC. GO and KEGG showed that 101 potential target enrichment in cancer and cell cycle regulation. By Venn analysis, CDK1 and CCNB1 were intersection targets, which could be used as potential targets for the action of quercetin on HBV-related HCC. Moreover, the expression of CDK1 and CCNB1 was highly expressed in the high-risk group, while the OS rate was low. The 1-year, 3-year and 5-year area under the curve (AUC) curves of CDK1 and CCNB1 were 0.724, 0.676, 0.622 and 0.745, 0.678, 0.634, respectively. Moreover, experimental results also showed that quercetin inhibited cell proliferation and reduced CDK1 expression in Hep3B and HepG2215 cells. The expressions of HBsAg and HBeAg in HepG2215 cell supernatant and cell gradually decreased with the increase of intervention time of quercetin and CDK1 inhibitor.

CONCLUSIONS:

Quercetin is a key ingredient of anti-HBV-related HCC activity and inhibits HBV replication in SNRS by inhibiting CDK1.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quercetina / Replicación Viral / Medicamentos Herbarios Chinos / Proteína Quinasa CDC2 / Panax / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Chem Biol Drug Des Asunto de la revista: BIOQUIMICA / FARMACIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Quercetina / Replicación Viral / Medicamentos Herbarios Chinos / Proteína Quinasa CDC2 / Panax / Neoplasias Hepáticas Límite: Humans Idioma: En Revista: Chem Biol Drug Des Asunto de la revista: BIOQUIMICA / FARMACIA / FARMACOLOGIA Año: 2024 Tipo del documento: Article Pais de publicación: Reino Unido